L&G Pharma Breakthrough UCITS ETF (EUR) | BIOTRegístrese para Ver el Rating |
Cómo se ha comportado este fondo | 31/10/2024 |
Crecimiento de 1.000 (EUR) | Gráfico Avanzado |
Fondo | 16,8 | 5,7 | -3,1 | -14,0 | 5,1 | |
+/-Cat | -2,5 | 8,7 | 9,7 | -15,1 | 1,0 | |
+/-Ind | -9,1 | -1,3 | -0,1 | -23,9 | -3,4 | |
Categoría: RV Sector Biotecnología | ||||||
Benchmark de la Categoría: Morningstar Gbl Biotechnolo... |
Estadística Rápida | ||
Precio de Cierre 20/11/2024 | EUR 9,67 | |
Cambio del día | 1,21% | |
Categoría Morningstar™ | RV Sector Biotecnología | |
Volumen | 1107 | |
Bolsa | BORSA ITALIANA S.P.A. | |
ISIN | IE00BF0H7608 | |
Patrimonio (Mil) 20/11/2024 | USD 16,15 | |
Patrimonio Clase (Mil) 20/11/2024 | USD 16,15 | |
Gastos Corrientes 14/02/2024 | 0,49% |
Objetivo de inversión: L&G Pharma Breakthrough UCITS ETF (EUR) | BIOT |
The investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. In order to achieve this investment objective, the Fund will seek to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). It will do so by investing primarily in a portfolio of equity securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index and may have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position. |
Returns | |||||||||||||
|
Gestión | ||
Nombre del gestor Fecha Inicio | ||
- - | ||
Creación del fondo 18/01/2018 |
Anuncio publicitario |
Benchmark de la Categoría | |
Benchmark de fondos | Benchmark Morningstar |
Solactive Pharma Breakthrough V NR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Qué posee el fondo L&G Pharma Breakthrough UCITS ETF (EUR) | BIOT | 19/11/2024 |
|
|
5 mayores posic. | Sector | % |
Pharma Mar SA | Salud | 4,97 |
Agios Pharmaceuticals Inc | Salud | 3,59 |
InnoCare Pharma Ltd | Salud | 3,48 |
Xeris Biopharma Holdings Inc | Salud | 3,42 |
Bristol-Myers Squibb Co | Salud | 3,41 |
Incremento Reducción Nuevo desde la anterior cartera | ||
L&G Pharma Breakthrough UCITS ETF (EUR) | BIOT |